Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease.

It has been a banner year for biotech buyouts, and these are two of the prime targets.

The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...

Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials compare?

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...

Spyre Therapeutics SYRE has given investors a classic biotech dilemma. The pipeline is advancing, the cash balance is large ...

Short interest data from late June 2026 highlights deeply divided investor sentiment across the healthcare sector. Strong bearish bets remain heavily concentrated in speculative biotech plays like Int ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Neuren shares are soaring after a major European regulatory breakthrough brought its lead drug one step closer to a lucrative ...

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an ...